Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis

• Status: Completed
• Trial end date: 2018-02-02
• Target enrollment: 0
• Participant gender: All

Summary

The protocol will measure a number of cytokines in addition to vascular endothelial growth factor in response to 0.3mg Lucentis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Louis C. Glazer, MD; Vitreo-Retinal Associates, Michigan
• Collaborators: Genentech, Inc.; Michigan State University
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Diagnosis of diabetes mellitus

• Best corrected visual acuity 20/32 - 20/320

• Diabetic macular edema involving the center of the macula

• Optical coherence tomography central subfield thickness of at least 250 microns

Exclusion Criteria:

• History of anti-vascular endothelial growth factor treatment in the past 12 months

• Any diabetic macular edema treatment in the past 4 months

• Heart attack, stroke, transient ischemic attack or acute congestive heart failure within 4 months